[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053228":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":148,"collaborators":19,"id":150,"slug":19,"hasResults":151,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":19,"eligibilityCriteria":155,"healthyVolunteers":151,"sex":156,"minAge":157,"maxAge":19,"enrollmentInfo":158,"targetDuration":19,"studyType":161,"phases":162,"briefSummary":164,"conditions":165,"keywords":167,"overallStatus":42,"whyStopped":19,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":181},{"fullName":5,"class":6},"AstraZeneca","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"AZD0120","EXPERIMENTAL","AZD0120 will be administrated in one infusion",[13],"Biological: AZD0120",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"BIOLOGICAL","AZD0120 is a BCMA\u002FCD19 dual CAR T cell product under investigation for early-line treatment in subjects with multiple myeloma",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"AstraZeneca Clinical Study Information Center","CONTACT","1-877-240-9479","information.center@astrazeneca.com",[27,41,51,60,69,78,87,96,105,113,122,131,139],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":19},"Research Site","WITHDRAWN","Phoenix","Arizona","85054","United States","US",{"type":36,"coordinates":37},"Point",[38,39],-112.07404,33.44838,{"lat":39,"lon":38},{"facility":28,"status":42,"city":43,"state":44,"zip":45,"country":33,"countryCode":34,"cosmosGeoPoint":46,"geoPoint":50,"contacts":19},"RECRUITING","Duarte","California","91010",{"type":36,"coordinates":47},[48,49],-117.97729,34.13945,{"lat":49,"lon":48},{"facility":28,"status":42,"city":52,"state":53,"zip":54,"country":33,"countryCode":34,"cosmosGeoPoint":55,"geoPoint":59,"contacts":19},"Denver","Colorado","80218",{"type":36,"coordinates":56},[57,58],-104.9847,39.73915,{"lat":58,"lon":57},{"facility":28,"status":42,"city":61,"state":62,"zip":63,"country":33,"countryCode":34,"cosmosGeoPoint":64,"geoPoint":68,"contacts":19},"Tampa","Florida","33612",{"type":36,"coordinates":65},[66,67],-82.45843,27.94752,{"lat":67,"lon":66},{"facility":28,"status":42,"city":70,"state":71,"zip":72,"country":33,"countryCode":34,"cosmosGeoPoint":73,"geoPoint":77,"contacts":19},"Atlanta","Georgia","30322",{"type":36,"coordinates":74},[75,76],-84.38798,33.749,{"lat":76,"lon":75},{"facility":28,"status":42,"city":79,"state":80,"zip":81,"country":33,"countryCode":34,"cosmosGeoPoint":82,"geoPoint":86,"contacts":19},"Iowa City","Iowa","52242",{"type":36,"coordinates":83},[84,85],-91.53017,41.66113,{"lat":85,"lon":84},{"facility":28,"status":29,"city":88,"state":89,"zip":90,"country":33,"countryCode":34,"cosmosGeoPoint":91,"geoPoint":95,"contacts":19},"Rochester","Minnesota","55905",{"type":36,"coordinates":92},[93,94],-92.4699,44.02163,{"lat":94,"lon":93},{"facility":28,"status":42,"city":97,"state":98,"zip":99,"country":33,"countryCode":34,"cosmosGeoPoint":100,"geoPoint":104,"contacts":19},"St Louis","Missouri","63110",{"type":36,"coordinates":101},[102,103],-90.19789,38.62727,{"lat":103,"lon":102},{"facility":28,"status":42,"city":106,"state":106,"zip":107,"country":33,"countryCode":34,"cosmosGeoPoint":108,"geoPoint":112,"contacts":19},"New York","10016",{"type":36,"coordinates":109},[110,111],-74.00597,40.71427,{"lat":111,"lon":110},{"facility":28,"status":42,"city":114,"state":115,"zip":116,"country":33,"countryCode":34,"cosmosGeoPoint":117,"geoPoint":121,"contacts":19},"Nashville","Tennessee","37203",{"type":36,"coordinates":118},[119,120],-86.78444,36.16589,{"lat":120,"lon":119},{"facility":28,"status":29,"city":123,"state":124,"zip":125,"country":33,"countryCode":34,"cosmosGeoPoint":126,"geoPoint":130,"contacts":19},"Dallas","Texas","75235",{"type":36,"coordinates":127},[128,129],-96.80667,32.78306,{"lat":129,"lon":128},{"facility":28,"status":42,"city":132,"state":124,"zip":133,"country":33,"countryCode":34,"cosmosGeoPoint":134,"geoPoint":138,"contacts":19},"Houston","77030",{"type":36,"coordinates":135},[136,137],-95.36327,29.76328,{"lat":137,"lon":136},{"facility":28,"status":42,"city":140,"state":141,"zip":142,"country":33,"countryCode":34,"cosmosGeoPoint":143,"geoPoint":147,"contacts":19},"Charlottesville","Virginia","22903",{"type":36,"coordinates":144},[145,146],-78.47668,38.02931,{"lat":146,"lon":145},{"type":149,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100053228",false,"NCT07073547","A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)","A Modular, Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, a Dual-targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19 in Participants With Multiple Myeloma (DURGA-2)","Inclusion Criteria:\n\nAge:\n\n* Males and females ≥18 years of age at the time of consent\n\nType of Participant and Disease Characteristics:\n\n* Participant must have documented diagnosis of MM per IMWG diagnostic criteria\n* ECOG performance status of 0 or 1.\n* Adequate organ and bone marrow function.\n\nFor NDMM participants:\n\n* Participants on Module 1: Newly diagnosed multiple myeloma (NDMM) without prior anti- myeloma therapy (no more than 2 cycles of induction therapy before enrollment are acceptable)\n* For participants on Module 2: Newly diagnosed MM with a minimum of 4 cycles and a maximum of 6 cycles of induction therapy completed prior to screening\n* Classified as high-risk MM\n\nFor Early Relapsed or Primary Refractory MM (1 or 2 prior lines of therapy) participants:\n\n* Have received and failed 1 or 2 lines of anti-myeloma therapy\n* Have received a proteasome inhibitor (PI) and immunomodulatory drug (IMiD) as part of their previous therapy\n* Have documented evidence of progressive disease based on investigator's determination of response by the IMWG criteria within 1 year of starting treatment, or on or within 6 months of completing treatment of the subject's last line of anti-myeloma therapy, or have confirmed progressive disease within 6 months prior to screening and who are subsequently determined to be refractory or non-responsive to their most recent anti-myeloma treatment regimen\n\nGeneral Exclusion Criteria:\n\n* Have received prior treatment with CAR T therapy directed at any target\n* Known active, or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of multiple myeloma\n* Active or history of plasma cell leukemia at the time of screening\n* Seropositive for human immunodeficiency virus (HIV)\n* Active Hepatitis B infection\n* Active Hepatitis C infection\n* Serious underlying medical condition","ALL","18 Years",{"count":159,"type":160},40,"ESTIMATED","INTERVENTIONAL",[163],"PHASE1","This is an interventional, modular, open-label, multicenter study to primarily evaluate the safety and tolerability of AZD0120 in adult participants with multiple myeloma (MM).",[166],"Multiple Myeloma",[168,169,170,171],"Multiple myeloma","BCMA","CD19","CAR-T","2026-07-10",{"date":174,"type":175},"2026-07-13","ACTUAL",{"date":177,"type":175},"2025-07-31",{"date":179,"type":160},"2028-05-26",{"name":5,"class":6},13]